Litcius/Paper detail

Effectiveness of sulfadoxine–pyrimethamine plus amodiaquine and dihydroartemisinin–piperaquine for seasonal malaria chemoprevention in Uganda: a three-arm, open-label, non-inferiority and superiority, cluster-randomised, controlled trial

Anthony Nuwa, K. Scott Baker, Richard Kajubi, Chukwudi A Nnaji, Katherine Theiss-Nyland, Musa Odongo, Tonny Kyagulanyi, Jane Nabakooza, David Salandini, Victor Asua, Maureen Nakirunda, Christian Rassi, Damian Rutazaana, Richard Achuma, Patrick Sagaki, John Baptist Bwanika, Godfrey Magumba, Adoke Yeka, Samuel L. Nsobya, Moses R. Kamya, James Tibenderana, Jimmy Opigo

2025The Lancet Infectious Diseases13 citationsDOI

Topics & Concepts

AmodiaquineMedicineMalariaOpen labelSulfadoxineSulfadoxine/pyrimethaminePiperaquineRandomized controlled trialPyrimethamineInternal medicineArtemisininPlasmodium falciparumImmunologyMalaria Research and ControlPharmaceutical Quality and CounterfeitingParasitic Diseases Research and Treatment
Effectiveness of sulfadoxine–pyrimethamine plus amodiaquine and dihydroartemisinin–piperaquine for seasonal malaria chemoprevention in Uganda: a three-arm, open-label, non-inferiority and superiority, cluster-randomised, controlled trial | Litcius